https://research.ouhsc.edu/news Parent Page: News id: 26727 Active Page: details id: 26917

News

Research News – Monday, July 1, 2024


Published: Monday, July 1, 2024

OUHSC ANNOUNCEMENTS
 
NEW OUHSC Research Incentive Program: The Provost is pleased to announce the launch of a new Research Incentive Program, effective July 1, 2024, designed to support and reward faculty efforts in securing high-level research funding from the National Institutes of Health (NIH) and other federal agencies. This initiative program underscores the campus’ commitment to fostering a vibrant research environment, leading health innovation and encouraging outstanding contributions from OUHSC faculty. The Research Incentive Program offers one-time financial incentives for faculty who achieve significant research milestones.  For additional information please see the attached documents.
 
CHANGES TO THE HRPP / IRB FEE COLLECTION PROCESS:
It is University HRPP policy that the HSC HRPP charges an HRPP / IRB fee for initial and continuing review of industry sponsored human research projects.  Payment of these fees is the responsibility of the PI’s department submitting the application, and is due upon completion of HRPP / IRB review.  Fees are due regardless of review outcome, sponsor contract status, or enrollment status.  Effective July 1, 2024, new study submissions that are subject to HRPP / IRB fees will require the department’s Chartfield spread (CFS) number in the Application. Upon completion of the HRPP / IRB review, the HRPP Office will enter the cost transfer from the department’s CFS, and will send the department the transfer information along with documentation of the invoice for the department to send to the study funding entity for reimbursement purposes.
Please contact Donna Hogan at donna-hogan@ouhsc.edu for any questions you may have about the new process.
 
OUHSC Funding Opportunities
 
Oklahoma Shared Clinical and Translational Resources
Clinical and Translational Research Pilot (CTRP) Grants
Call for Proposals 2024
The Oklahoma Clinical and Translational Science Institute (OCTSI) and Oklahoma Shared Clinical and Translational Resources (OSCTR) is soliciting applications for its Clinical and Translational Research Pilot (CTRP) Grants Program.
Approved CTRP grants will be funded for a period starting January 1, 2025 contingent on NIH approval of just in time (JIT) information. All funds are required to be expended by December 31, 2025.
Deadline is Friday, August 6, 2024
 
The Searle Scholars Program makes grants to selected universities and research institutes to support the independent research of exceptional young faculty in the biomedical sciences and chemistry. Applicants for the 2025 competition are expected to be pursuing independent research careers in biochemistry, cell biology, genetics, immunology, neuroscience, pharmacology, and related areas in chemistry, medicine, and the biological sciences. The 2025 award will be in the amount of $300,000 ($100,000 per year for three years).  Details can be found at https://searlescholars.org/ and in the attached announcement. 
 
Cycles I-III PHF TAG Grant Program Deadline: ROLLING APPLICATIONS
The TAG program replaces the Equipment grant program. The primary objective of the PHF TAG program is to provide partial funding for critically needed research equipment that could be transformative for the research mission at OUHSC. This program is fully aligned with Pillar 1 of the Strategic Plan. The TAG program will proactively and with the help of a committee address campus-wide needs and fill critical gaps, with the goals to grow the research enterprise, expand innovative technology and research infrastructure, and promote addition of new cutting-edge technology on campus. Funding priority will be given to research equipment that will permit OUHSC investigators to be more competitive for external funding and provides support to multiple users. Funds may be used for equipment to be purchased as part of a recruitment package for new faculty or for equipment to support the research of current faculty. If the funds will be used for a new recruit, the recruit must have signed the offer letter with a specific start date or specific start date time frame. Equipment and/or technology funded by PHF is expected to be made available to all researchers at OUHSC, whenever possible. All OUHSC Assistant, Associate, or Full Professors are eligible to apply. Applicants are required to match requested funds. The maximum allowable budget for this program is $500,000 (PHF funding: $250,000; Applicant funding: $250,000). The minimum allowable budget for this program is $60,000 (PHF funding: $30,000; Applicant funding:  $30,000). Only one application will be accepted per investigator per year.  
 
Presbyterian Health Foundation (PHF) Bridge Grant Program – Request for Applications
  • Cycle III PHF Bridge Grant Program Deadline: Friday, August 2, 2024
The primary objective of the PHF Bridge Grant Program is to provide funding to enhance OUHSC faculty competitiveness for extramural funding. OUHSC Principal Investigators are eligible if they meet the following criteria: 1) have submitted an extramural application within the past 18 months that was scored but not funded, 2) are requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs; and 3) received a review that ranks applications and provides critiques. This program can now provide funding for up to $75,000 for one year. Guidelines and Application Form are attached. If you have any questions, please email  VPR@ouhsc.edu.
 
New Clinical Study Opportunities
***************************************************
Please note this is NOT a solicitation for study subjects
***************************************************
Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:
  • Phase 1b Open Label Basket Study of Ray121 to inhibit complements classical Pathway in Immunological Diseases (Rainbow Trial) targeting the complement classical pathway in patients with complement mediated autoimmune diseases, such as:
    • Antiphospholipid syndrome (APS) Bullous pemphigoid (BP)
    • Behçet’s Syndrome (BS)                            Dermatomyositis (DM)
    • Immune-mediated necrotizing myopathy (IMNM)
    • Immune Thrombocytopenia (ITP)
  • A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age
  • ABBV-668 is an inhibitor of receptor-interacting protein kinase 1 (RIPK1) being investigated for the treatment of ulcerative colitis.
  • Systemic Lupus Erythematosus (SLE) ALPN-101, a first-in-class dual CD28/ICOS antagonist. CD28 and ICOS are key costimulatory molecules that likely play critical roles in multiple autoimmune and inflammatory diseases.
  • Potential hereditary haemochromatosis trial researching ferroportin inhibitor in patients unable to tolerate phlebotomy treatments
  • Pfizer Announces a New Research Grants RFP in Multiple Myeloma
    • Projects that will be considered for Pfizer support will focus on generating evidence on priority gaps in the use of elranatamab in multiple myeloma across lines of treatment.
  • Pfizer Global Medical Grants Announces a New Education RFP in Cervical Cancer
    • The goal of this RFP is to support education for medical oncologists, gynecologic oncologists, pharmacists, eye care providers, nurse practitioners and physician assistants working in the oncology setting caring for patients with r/m cervical cancer relating to treatments, management of adverse events, and long-term outcomes.
Please contact Scott Davis at scott-davis@ouhsc.edu if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.
 
 
NIH Notices
 
(NOT-HL-24-020)
 
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.
 
NIH Funding Opportunities
 
 
 
 
 
 
 
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) (PAR-24-223)
Application Deadline:  February 05, 2025
 
 
 
 
 
Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed) (PAR-24-243)
Application Deadline: October 05, 2024 and February 05, 2025 
 
 
 
 
(RFA-MH-25-195)
Application Deadline:  October 18, 2024
 
 
The NINDS Human Cell and Data Repository (U24 - Clinical Trial Not Allowed) (RFA-NS-24-040)
Application Deadline:  October 17, 2024

Documents to download